review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | C M White | |
J C Song | |||
P2860 | cites work | Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 |
Simvastatin in severe hypercholesterolaemia: a placebo controlled trial | Q34358043 | ||
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. | Q34429041 | ||
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia | Q34439645 | ||
Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study | Q36246409 | ||
Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers | Q36434446 | ||
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q39522420 | ||
Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)? | Q46602143 | ||
Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. | Q50890944 | ||
Fibrinogen is an independent marker for thoracic aortic atherosclerosis. | Q50907848 | ||
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. | Q51552694 | ||
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. | Q51576971 | ||
Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. | Q51581527 | ||
Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 236-241 | |
P577 | publication date | 2001-02-01 | |
P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
P1476 | title | Do HMG-CoA reductase inhibitors affect fibrinogen? | |
P478 | volume | 35 |
Q36608415 | Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. |
Q37870867 | Chronic Chlamydia pneumoniae infection in patients with coronary disease. Relation with increased fibrinogen values |
Q34979669 | Early statin therapy for acute coronary syndromes |
Q44003335 | Effect of ciprofibrate on C-reactive protein and fibrinogen levels |
Q35200997 | Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes |
Q44378136 | Hemostatic effects of atorvastatin versus simvastatin |
Q42754391 | Hemostatic effects of simvastatin in subjects with impaired fasting glucose. |
Q44479268 | The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study |
Q36059492 | The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology |